Rebiopsy of lung cancer after treatment no longer works
Part of Cancer, Lungs & breathing clinical trials.
This trial studies patients with lung cancer whose disease has continued to grow despite immunotherapy. It involves taking a new tissue sample (a rebiopsy) to help doctors understand what changed during treatment and guide next steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell or small cell lung cancer
- You previously received immunotherapy (often called ICI) and your cancer kept progressing while on it
- You are at least 18 years old when you sign the consent form
- You can sign written consent yourself (or are not under legal guardianship)
- Doctors can safely take a new tissue sample using local anesthesia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a detailed lung-cancer database by collecting clinical and lab information from people newly diagnosed. It aims to help doctors better understand lung cancer and how patients are treated from the start.
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
This trial looks at information and tissue from people with stage I to stage IIIA non-small cell lung cancer (NSCLC) who have surgery, sometimes with chemotherapy before surgery. Researchers want to understand why cancers come back (resistance) and how to better target treatments later.
This study collects real-world information about people with lung cancer who get newer kinds of cancer drugs. It aims to understand how these innovative therapies work in everyday care and help future research.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This study looks at genetic information from tumor tissue of people with non-small cell lung cancer who had immunotherapy before surgery but still had some cancer cells left. The goal is to understand why the cancer did not completely respond to treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.